Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 30, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2029

Conditions

ObesityVascular Health

Interventions

DRUG

Empagliflozin

12 week treatment with 10mg empagliflozin daily

DRUG

Placebo

12 week treatment with 10mg placebo daily

Trial Locations (1)

RECRUITING

Harry S. Truman Memorial, Columbia, MO, Columbia

All Listed Sponsors

collaborator

University of Missouri-Columbia

OTHER

lead

VA Office of Research and Development

FED

NCT06745063 - Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity | Biotech Hunter | Biotech Hunter